New Class of Potential Antibiotics Licensed by BSKB Medical Ventures, LLC. NEW VENTURE IS CALLED PYRO PHARMACEUTICALS, INC.

COSTA MESA CA USA - BSKB Medical Ventures, LLC., announced today it has exclusively licensed the rights to commercialize a technology relating to a new class of potential antibiotics from California State University, Fullerton.

NEW DRUG COMPANY LAUNCHED:

To exploit this technology, BSKB Medical Ventures recently established a new company, Pyro Pharmaceuticals, Inc. The new drug company has since licensed the technology from CSUF. In addition, Pyro Pharmaceuticals, Inc. closed a Series "A" financing round in November 2001.

NOVEL METABOLIC PATHWAY:

The licensed technology results from the research of Christopher R. Meyer, Ph.D., Associate Professor of Chemistry & Biochemistry. Dr. Meyer's work focuses on a novel metabolic pathway that is essential for bacterial viability.

NOVEL CLASS OF ANTIBIOTICS:

"Dr. Meyer has identified a unique target that will be used to develop a novel class of antibiotics against a wide range of multi-drug resistant pathogenic microorganisms," says Alan M. Schechter, Managing Director of BSKB Medical Ventures and the Chairman & CEO of the newly formed company.

PYRO EXPECTS TO RECEIVE BROAD PATENT COVERAGE:

"The Company expects to receive broad patent coverage on the pathway and on selective drug candidates," states Leonard R. Svensson, J.D., Partner, Birch Stewart Kolasch & Birch, LLP, the Company's patent counsel.

ABOUT THE COMPANIES:

BSKB Medical Ventures is a strategic management consulting firm specializing in medical device, biotech, pharmaceutical, diagnostic and healthcare business ventures.

Birch Stewart Kolasch & Birch, with offices in Costa Mesa CA and Falls Church VA, is a full service intellectual property law firm. Last year it ranked fourth in the US in the number of patents granted for its clients.